5-羟基-3-(2-羟基-4-甲氧基苯基)-8,8-二甲基-10-(3-甲基丁-2-烯基)吡喃并[5,6-g]苯并吡喃-4-酮 | 30431-68-6

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 异黄酮类化合物
• 中文名称: 5-羟基-3-(2-羟基-4-甲氧基苯基)-8,8-二甲基-10-(3-甲基丁-2-烯基)吡喃并[5,6-g]苯并吡喃-4-酮
• 英文名称: Auriculin
• 英文别名: 5-hydroxy-7-(2-hydroxy-4-methoxyphenyl)-2,2-dimethyl-10-(3-methylbut-2-enyl)pyrano[3,2-g]chromen-6-one
• CAS: 30431-68-6
• 化学式: C₂₆H₂₆O₆
• 分子量: 434.5
• InChiKey: VQGWUEFARIAFPF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.8
• 重原子数：
  32
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  85.2
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• Pharmaceutical compositions of drug-oligomer conjugates and methods of treating diseases therewith
  申请人：——

  公开号：US20030069170A1

  公开（公告）日：2003-04-10

  Pharmaceutical compositions that include a drug-oligomer conjugate, a fatty acid component, and a bile salt component are described. The drug is covalently coupled to an oligomeric moiety. The fatty acid component and the bile salt component are present in a weight-to-weight ratio of between 1:5 and 5:1. Methods of treating diseases in a subject in need of such treatment using such pharmaceutical compositions are also provided, as are methods of providing such pharmaceutical compositions.

  描述了包括药物-寡聚物共轭物、脂肪酸成分和胆盐成分的药物组合物。药物以共价键连接到寡聚物基团上。脂肪酸成分和胆盐成分以1:5至5:1的重量比存在。还提供了利用这种药物组合物治疗需要此类治疗的受试者的方法，以及提供这种药物组合物的方法。
• Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
  申请人：——

  公开号：US20030228275A1

  公开（公告）日：2003-12-11

  A non-polydispersed mixture of conjugates in which each conjugate in the mixture comprises a drug coupled to an oligomer that includes a polyalkylene glycol moiety is disclosed. The mixture may exhibit higher in vivo activity than a polydispersed mixture of similar conjugates. The mixture may be more effective at surviving an in vitro model of intestinal digestion than polydispersed mixtures of similar conjugates. The mixture may result in less inter-subject variability than polydispersed mixtures of similar conjugates.

  披露了一种非多分散混合物，其中混合物中的每个共轭物包括与包含聚乙二醇基团的寡聚物偶联的药物。该混合物可能表现出比类似共轭物的多分散混合物更高的体内活性。该混合物可能比类似共轭物的多分散混合物更有效地在体外模拟肠道消化模型中存活。该混合物可能导致比类似共轭物的多分散混合物更少的受试者间变异性。
• Biosynthetic polypeptides utilizing non-naturally encoded amino acids
  申请人：Cho Sung Ho

  公开号：US20060019347A1

  公开（公告）日：2006-01-26

  Modified biosynthetic polypeptide molecules, methods for manufacturing, and uses thereof are provided.

  提供了修改的生物合成多肽分子、制造方法和使用方法。
• Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
  申请人：——

  公开号：US20040017387A1

  公开（公告）日：2004-01-29

  Pharmaceutical compositions that include a drug and/or drug-oligomer conjugate, a fatty acid component and a bile salt component, or a bile salt component without a fatty acid component are described. The drug can be covalently coupled to an oligomeric moiety. The fatty acid component and the bile salt component, when together, can be present in a weight-to-weight ratio of between 1:15 and 15:1 or any value between. Methods of treating diseases in a subject in need of such treatment using the pharmaceutical compositions of this invention are also provided, as well as methods of providing such pharmaceutical compositions.

  本发明描述了包括药物和/或药物寡聚物共轭物、脂肪酸成分和胆盐成分或仅胆盐成分的制药组合物。药物可以与寡聚物基团共价耦合。当脂肪酸成分和胆盐成分一起存在时，它们的重量比可以在1:15和15:1之间或任何值之间。本发明还提供了使用此制药组合物治疗需要此类治疗的患者的疾病的方法，以及提供此类制药组合物的方法。
• Biosynthetic Polypeptides Utilizing Non-Naturally Encoded Amino Acids
  申请人：CHO Ho Sung

  公开号：US20100048871A1

  公开（公告）日：2010-02-25

  Modified biosynthetic polypeptide molecules, methods for manufacturing, and uses thereof are provided.

  本发明提供了改良的生物合成多肽分子的制造方法和使用方法。